Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.89 CHF | +2.38% | -8.62% | +97.42% |
Apr. 24 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
Apr. 17 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Sales 2022 | 17.99M 19.7M | Sales 2023 | 33.56M 36.77M | Capitalization | 128M 141M |
---|---|---|---|---|---|
Net income 2022 | -14M -15.34M | Net income 2023 | -13M -14.24M | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.19M | Net cash position 2023 | 12M 13.14M | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | 80 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.71% |
1 day | +2.38% | ||
1 week | -8.62% | ||
Current month | +13.70% | ||
1 month | +23.04% | ||
3 months | +53.79% | ||
6 months | +171.26% | ||
Current year | +97.42% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 23-02-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 18-06-13 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 6.89 | +2.38% | 201,239 |
24-04-24 | 6.73 | -5.34% | 430,265 |
24-04-23 | 7.11 | -12.44% | 601,803 |
24-04-22 | 8.12 | +8.27% | 278,390 |
24-04-19 | 7.5 | -0.53% | 112,630 |
Delayed Quote Swiss Exchange, April 25, 2024 at 11:31 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+97.42% | 271M | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- KURN Stock